Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy
NCT ID: NCT02144441
Last Updated: 2015-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2014-06-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
NCT01240200
Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin
NCT01136746
Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings
NCT00177398
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
NCT02197520
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
NCT00191464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient self-administered insulin
The study's only arm
glargine and aspart
Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
glargine and aspart
Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current HUP locations are Founders 12, Founders 14, Silverstein 11, and Rhoads 1.
* Age 18 years or older.
* Type-1 or type-2 diabetes mellitus requiring home basal-bolus insulin therapy administered via subcutaneous injection (not pump).
* Patient manages own basal-bolus insulin therapy at home without assistance, including measuring own blood glucose (at least at mealtimes) and administering own subcutaneous insulin.
* Patient is willing to use the following insulin products: rapid-acting insulin aspart via insulin pen (NovoLog) and long-acting insulin glargine via vial and syringe (Lantus).
* Most recent hemoglobin A1c was measured within past 6 months and was \<7.5%.
* Active order for in-hospital basal-bolus or sliding-scale insulin.
* Patient is willing and able to record their self-measured blood glucose results, doses of insulin that they self-administer, a food journal, and exercise log.
* Clinical care team agrees with study inclusion.
Exclusion Criteria
* Inability to perform the activities required by the trial.
* Primary reason for admission was hyperglycemia, hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma, a psychiatric condition, acute alcohol poisoning, or acute drug ingestion.
* Order for a newly-prescribed or increased dose of a previously-prescribed corticosteroid.
* Enteral or parenteral nutrition.
* Expected length of stay \<48h, as determined by treating physician.
* At risk for self-harm, as determined by 1-to-1 status placement.
* Pregnant, as recorded on medical record.
* Cannot understand, speak, and read English.
* Patient does not wish to utilize Novolog and Lantus while in the hospital.
* Prior enrollment in this trial.
* Do not resuscitate status.
* Inability to give written informed consent.
* Clinical care team disagrees with study inclusion.
* Patient has limited mobility such that they cannot safely access the bedside medication lockbox.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sean Hennessy, PharmD, PhD
Role: PRINCIPAL_INVESTIGATOR
Perelman School of Medicine at the University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Acton EK, Leonard CE, Schutta MH, Cardillo S, Troxel AB, Trotta R, Hennessy S. Challenges in recruiting subjects to a pilot trial of patient-managed in-hospital insulin. BMC Res Notes. 2015 Oct 1;8:523. doi: 10.1186/s13104-015-1480-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
819840
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.